🩸September is #BloodCancerAwarenessMonth and we’re doing our part to turn the month red. There are many types of #bloodcancer – each with different symptoms, treatments, and prognoses. #TeamArvinas is focused on raising awareness and researching treatment options for non-Hodgkin Lymphoma. Join us and others in raising awareness of blood cancer this month. Get involved here: https://bit.ly/47aC8Rm
Arvinas
Biotechnology Research
New Haven, Connecticut 22,279 followers
Leading the way in targeted protein degradation therapeutics
About us
Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-102, targeting LRRK2 for neurodegenerative disorders; and ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma. Based in the biotech hub of New Haven, CT, Arvinas is driven by an industry-leading team dedicated to improving the lives of people living with serious diseases. For more information, visit www.arvinas.com. Community Guidelines: http://bit.ly/ArvinasCG
- Website
-
www.arvinas.com
External link for Arvinas
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- New Haven, Connecticut
- Type
- Public Company
- Founded
- 2013
Locations
-
Primary
395 Winchester Ave.
5 Science Park
New Haven, Connecticut 06511, US
Employees at Arvinas
Updates
-
We were thrilled to welcome Rebecca Surran from News 12 Connecticut to #Arvinas for an exclusive tour of our labs. She sat down with Chief Scientific Officer Angela Cacace to explore our groundbreaking research and discuss how Arvinas is working to pursue new treatments to patients facing life-altering diseases. Don’t miss this insightful interview that highlights the science and dedication behind our mission. Check it out here: https://rb.gy/r9t4qo #TeamArvinas #Innovation #TPD #ProteinDegradation
-
We're excited to celebrate a milestone achieved by talented members of our platform biology team – the successful completion of our first fully automated High Throughput Screen (HTS) to identify new degrader chemical matter for important disease modifying targets using the Thermo Fisher Scientific Robot, UbiQTron! This accomplishment underscores our dedication to leveraging cutting-edge technology in degrader discovery. Investing in automation such as machine learning and AI is critical to advancing our research and pushing the boundaries of #innovation in #proteindegradation. Nice work, #TeamArvinas!
-
As a Medical Science Liaison, Eileen Rich fosters relationships with US healthcare providers to gather valuable insights to inform our clinical trial designs and research. Her background as an oncology nurse deepens her connection to her work, supporting #Arvinas' mission to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC® protein degradation platform. Eileen collaborates cross-functionally with members of #TeamArvinas in support of our goal of launching potential new therapeutic options for patients. When she's not working, Eileen enjoys hiking, traveling, and spending time with her husband and friends. With a son in college and a daughter finishing high school, she loves exploring new destinations and cherishes family time. #MeetTeamArvinas #TPD #WorkAtArvinas #EmployeeExperience #CompanyCulture
-
Today we recognize #BreastCancerResearchDay and celebrate the tremendous progress that has been made in #breastcancer research. However, we also recognize that 1-in-8 women will still be diagnosed with breast cancer in their lifetimes and there is an urgent need for new advancements. That’s why we continue our commitment to investigating new treatment options for those living with breast cancer and our mission to improve the lives of patients. #Biotech #Innovation #Science
-
Our Chairperson, CEO and President John Houston recently sat down with Ian Taylor, Ph.D., President, Research and Development to record a vlog where they discussed Ian's inspiring career journey, the invaluable guidance he received from his mentors, and his secrets to staying motivated. Tune in below to discover the lessons he's learned and the wisdom he shares. #Motivation #ProfessionalGrowth
I recently had a fantastic conversation with the Arvinas President of R&D, Ian Taylor, and it's a must-watch in my opinion! Ian shares his incredible career journey, the impact of his mentors, how he’s stayed motivated, and the valuable lessons he's learned along the way. Thanks for chatting, Ian! https://lnkd.in/e4vWvCX5
A Conversation with John Houston: Getting to Know Ian Taylor, President of R&D at Arvinas
John Houston on LinkedIn
-
Today’s #ScienceOfPROTAC focus is on the body’s primary mechanism for protein degradation - the ubiquitin-proteasome system. See how our PROTAC® technology aims to harness this system to destroy disease-causing proteins: https://bit.ly/3Sy8NKz #biotech #science
-
Our Chief Business Officer, Randy Teel, delves into the groundbreaking world of #targetedproteindegradation in a recent interview with Daniel Levine. He explores #TPDs evolution as a therapeutic strategy and the diverse therapeutic areas #Arvinas is pursuing. Tune in to the full interview to gain deeper insights into our innovative work. #TeamArvinas #Innovation #ProteinDegradation #Leadership
Randy Teel, chief business officer and interim chief financial officer of Arvinas, discusses protein degradation, its evolution as a therapeutic strategy, and the range of indications the company is pursuing. https://lnkd.in/gzsnvFtb
-
#NEWS: Today #Arvinas shared Q2 financial earnings and a business update. Read the release here: https://rb.gy/bpooti #investors #biotechnews
-
It was an honor to accept our award and recognize all of the honorees at this year's Healthcare & Life Sciences Awards. Thank you Greater New Haven Chamber of Commerce for awarding us Bioscience Company of the Year. Thank you BioCT for your endless support and thank you John Houston for representing #TeamArvinas!
Congratulations to the Greater New Haven Chamber of Commerce on executing another not-to-be-missed event, the ‘Heath Care & Life Sciences Awards’ at Canal Dock. We extend our congratulations to all the award winners, including Arvinas for Bioscience Company of the Year. BioCT board member John Houston accepted the award and was introduced by board member Carter Winstanley. We were also thrilled to see Mary Ann Melnick and BioLabs New Haven receive the Bioscience Innovator of the Year award—we feel so incredibly fortunate to call BioLabs our new home! #LifeSciences #NewHaven #GNHCC #Connecticut #Awards #BioCT